A Study of Mevrometostat With Enzalutamide in People With Prostate Cancer Who Have Previously Received Androgen Receptor Pathway Inhibitor Therapy

The purpose of this study is to find out whether mevrometostat in combination with enzalutamide delays cancer progression in people with metastatic castration-resistant prostate cancer (mCRPC) who have previously received enzalutamide, darolutamide, or apalutamide in the metastatic castration-sensitive prostate cancer (mCSPC) or non-metastatic castration-resistant prostate cancer (nmCRPC) setting but have not previously progressed on abiraterone.

NCT Number	NCT07592910
Lead Sponsor	Prostate Cancer Clinical Trials Consortium Collaborators: Pfizer, Dana-Farber Cancer Institute, Fred Hutchinson Cancer Center
Conditions	Metastatic Castrate Resistant Prostate Cancer (mCRPC), Prostate Cancer (Adenocarcinoma)
Enrollment	60 participants
Start Date	2026-08
Primary Completion	2029-05 (estimated)
Study Completion	2029-08 (estimated)
Updated on ClinicalTrials.gov	2026-05-18